CRC: Refractory metastatic CRC.
Gastric/GEJ: After ≥2 prior lines.
35 mg/m² orally BID with food D1-5, D8-12 of 28-day cycles.
Tablets: 15 mg/6.14 mg; 20 mg/8.19 mg
None listed.
Anemia (77%), Neutropenia (67%), Fatigue (52%), Nausea (48%), Thrombocytopenia (42%), Decreased Appetite (39%), Diarrhea (32%), Vomiting (28%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
May alter nucleoside analogue exposure.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Trifluridine incorporates into DNA interfering with function. Tipiracil prevents trifluridine metabolism.
Trifluridine t½: 1.4h. Tipiracil t½: 2.1h.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Lonsurf has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Lonsurf (trifluridine/tipiracil) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Trifluridine incorporates into DNA interfering with function. Tipiracil prevents trifluridine metabolism.
Anemia (77%), Neutropenia (67%), Fatigue (52%), Nausea (48%), Thrombocytopenia (42%), Decreased Appetite (39%), Diarrhea (32%), Vomiting (28%) Anemia 77% Neutropenia 67% Fatigue 52% Nausea 48% Thrombocytopenia 42% Decreased Appetite 39% Diarrhea 32% Vomiting 28%